Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
OBJECTIVE
The effects of the alpha-1-adrenergic blocker terazosin on blood pressure and fasting and postprandial glucose and lipid metabolism were assessed in type 2 diabetic patients with hypertension.


RESULTS
In this single-blind, randomized, crossover, placebo-controlled pilot study, thirteen patients were given terazosin for three months. Blood pressure and metabolic parameters were measured after a 14-hr overnight fast. In addition, a 800-calorie test meal was administered after placebo and terazosin to evaluate blood glucose and lipid changes following a standardized physiological stimulus. Blood pressure was significantly reduced and HDL-cholesterol significantly increased after terazosin. A significant decrease at fasting with a smaller reduction after the meal test was observed for free fatty acids when terazosin was given in comparison to placebo, suggesting an improvement in insulin resistance. A slight decrease in fasting and postprandial triglycerides was also observed. Cardiovascular risk, calculated according to the Framingham formula, was significantly reduced at the end of the terazosin treatment.


CONCLUSIONS
Antihypertensive treatment with terazosin is effective, has no adverse effects on fasting and postprandial glucose and lipid metabolisms, and appears to improve the cardiovascular risk profile of hypertensive patients with associated metabolic diseases.
Pasanisi
F
F
Dipartimento di Medicina Clinica e Sperimentale, Università Federico II, Napoli, Italy.
Imperatore
G
G
Vaccaro
O
O
Iovine
C
C
Ferrara
L A
LA
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000328:Adult; D000704:Analysis of Variance; D019540:Area Under Curve; D001786:Blood Glucose / Q000187:drug effects*; D008078:Cholesterol, LDL / Q000187:drug effects* / Q000378:metabolism; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004334:Drug Administration Schedule; D004435:Eating; D005215:Fasting; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D019518:Postprandial Period; D011224:Prazosin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011336:Probability; D016037:Single-Blind Method
D000317:Adrenergic alpha-Antagonists; D001786:Blood Glucose; D008078:Cholesterol, LDL; C041226:Terazosin; D011224:Prazosin